| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 125, 834-841, Copyright © 1989 by Endocrine Society
ARTICLES |
GA Nickols, AD Nana, MA Nickols, DJ DiPette and GK Asimakis
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77550.
Patients with humoral hypercalcemia of malignancy display markedly increased serum calcium levels, reduced blood pressure, and tachycardia. The causative agent, humoral hypercalcemia of malignancy factor [also called PTH-related protein (PTHrp)] has been shown to interact with PTH receptors in bone and kidney. We compared human PTHrp- (1-34) with rat PTH-(1-34) for the effects of each peptide on cardiovascular function in unrestrained conscious rats. Both PTHrp and PTH decreased blood pressure in a dose-dependent manner over the concentration range of 0.3-30 micrograms/kg. PTHrp was approximately 3- fold more potent than PTH, producing up to a 50 mm Hg decrease in pressure within 2 min at 10 micrograms/kg. Both peptides increased heart rate more than 70 beats/min at this dose. However, PTH appeared to exert greater efficacy and potency than PTHrp in increasing heart rate in vivo. In the isolated and perfused rat heart, PTHrp and PTH produced positive chronotropic and positive inotropic effects as well as increased coronary flow. PTHrp was more potent and more effective than PTH. The time courses of these effects in the perfused heart preparations indicated that both peptides produced maximal effects within 1 min, with all responses returning to baseline within 10 min. In isolated helical strips of rat aorta, PTHrp and PTH relaxed norepinephrine-contracted tissues in a concentration-dependent fashion. A functional endothelium was not required for the relaxing effects of either peptide. These studies indicate that PTHrp and PTH decrease blood pressure by relaxing vascular tissue in an endothelium- independent manner. Also, these peptides directly increased heart rate, contractility, and coronary flow. Since PTHrp has recently been found in normal human cells, these studies suggest the possibility of PTHrp as a regulator or modulator of cardiovascular function.
This article has been cited by other articles:
 |
|
 |
|
  A. Halapas, P. Lembessis, I. Mourouzis, C. Pantos, D. V. Cokkinos, A. Sourla, and M. Koutsilieris Experimental hyperthyroidism increases expression of parathyroid hormone-related peptide and type-1 parathyroid hormone receptor in rat ventricular myocardium of the Langendorff ischaemia-reperfusion model Exp Physiol, February 1, 2008; 93(2): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Welsch, E. Schordan, C. Coquard, T. Massfelder, N. Fiaschi-Taesch, J.-J. Helwig, and M. Barthelmebs Abnormal Renovascular Parathyroid Hormone-1 Receptor in Hypertension: Primary Defect or Secondary to Angiotensin II Type 1 Receptor Activation? Endocrinology, September 1, 2006; 147(9): 4384 - 4391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Maioli, V. Fortino, and A. Pacini Parathyroid Hormone-Related Protein in Preeclampsia: A Linkage Between Maternal and Fetal Failures Biol Reprod, December 1, 2004; 71(6): 1779 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andersson, E. Rydberg, and R. Willenheimer Primary hyperparathyroidism and heart disease -- a review Eur. Heart J., October 2, 2004; 25(20): 1776 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fritsch, V. Lindner, S. Welsch, T. Massfelder, M. Grima, S. Rothhut, M. Barthelmebs, and J.-J. Helwig Intravenous Delivery of PTH/PTHrP Type 1 Receptor cDNA to Rats Decreases Heart Rate, Blood Pressure, Renal Tone, Renin Angiotensin System, and Stress-Induced Cardiovascular Responses J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2588 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grohe, M. van Eickels, S. Wenzel, R. Meyer, H. Degenhardt, P. A Doevendans, M. P Heinemann, G. Ross, and K.-D. Schluter Sex-specific differences in ventricular expression and function of parathyroid hormone-related peptide Cardiovasc Res, February 1, 2004; 61(2): 307 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Funk, E. Migliati, G. Chen, H. Wei, J. Wilson, K. J. Downey, P. J. Mullarky, B. M. Coull, P. F. McDonagh, and L. S. Ritter Parathyroid hormone-related protein induction in focal stroke: a neuroprotective vascular peptide Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1021 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schorr, G. Taimor, H. Degenhardt, K. Weber, and K.-D. Schluter Parathyroid Hormone-Related Peptide Is Induced by Stimulation of alpha 1A-Adrenoceptors and Improves Resistance against Apoptosis in Coronary Endothelial Cells Mol. Pharmacol., January 1, 2003; 63(1): 111 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jansen, P. Gres, C. Umschlag, F. R. Heinzel, H. Degenhardt, K.-D. Schluter, G. Heusch, and R. Schulz Parathyroid hormone-related peptide improves contractile function of stunned myocardium in rats and pigs Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H49 - H55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Degenhardt, J. Jansen, R. Schulz, D. Sedding, R. Braun-Dullaeus, and K.-D. Schluter Mechanosensitive release of parathyroid hormone-related peptide from coronary endothelial cells Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1489 - H1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yamamoto, I. Morimoto, Y. Tanaka, N. Yanagihara, and S. Eto The Mutual Regulation of Arginine-Vasopressin and PTHrP Secretion in Dissociated Supraoptic Neurons Endocrinology, April 1, 2002; 143(4): 1521 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-D. Schluter, C. Katzer, K. Frischkopf, S. Wenzel, G. Taimor, and H. M. Piper Expression, Release, and Biological Activity of Parathyroid Hormone-Related Peptide From Coronary Endothelial Cells Circ. Res., May 12, 2000; 86(9): 946 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Barletta, M. L. De Feo, R. Del Bene, C. Lazzeri, S. Vecchiarino, G. La Villa, M. L. Brandi, and F. Franchi Cardiovascular Effects of Parathyroid Hormone: A Study in Healthy Subjects and Normotensive Patients with Mild Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1815 - 1821. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. J. Strewler The Physiology of Parathyroid Hormone-Related Protein N. Engl. J. Med., January 20, 2000; 342(3): 177 - 185. [Full Text] [PDF]
|
|
|
|
|
|
T. Neunteufl, R. Katzenschlager, C. Abela, Karam Kostner, B. Niederle, F. Weidinger, and T. Stefenelli Impairment of endothelium-independent vasodilation in patients with hypercalcemia Cardiovasc Res, November 1, 1998; 40(2): 396 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Selvais, J. E. Donckier, L. Rousseau, S. A. Ahn, J.-M. Ketelslegers, and M. F. Rousseau Hemodynamic Effects of Parathyroid Hormone-Related Peptide: Is There a Pathophysiological Relevance? J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1043a - 1044. [Full Text]
|
|
|
|
|
|
S. Yamamoto, I. Morimoto, K. Zeki, Y. Ueta, H. Yamashita, H. Kannan, and S. Eto Centrally Administered Parathyroid Hormone (PTH)-Related Protein(1-34) But Not PTH(1-34) Stimulates Arginine-Vasopressin Secretion and Its Messenger Ribonucleic Acid Expression in Supraoptic Nucleus of the Conscious Rats Endocrinology, January 1, 1998; 139(1): 383 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-D. Schluter and H. M. Piper Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide Cardiovasc Res, January 1, 1998; 37(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hara, Y.-M. Liu, L. Zhen, I. S. Cohen, H. Yu, P. Danilo Jr, K. Ogino, J. P. Bilezikian, and M. R. Rosen Positive Chronotropic Actions of Parathyroid Hormone and Parathyroid Hormone–Related Peptide Are Associated With Increases in the Current, If, and the Slope of the Pacemaker Potential Circulation, November 18, 1997; 96(10): 3704 - 3709. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Jiang, S. Morimoto, J. Yang, K. Fukuo, A. Hirotani, S. Kitano, and T. Ogihara Parathyroid Hormone–Related Protein Upregulates Interleukin-1ß–Induced Nitric Oxide Synthesis Hypertension, October 1, 1997; 30(4): 922 - 927. [Abstract] [Full Text]
|
|
|
|
|
|
M. Wolzt, L. Schmetterer, G. Dorner, G. Zelger, J. Entlicher, S. Kapiotis, and H.-G. Eichler Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1-34) in Humans J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2548 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jono, Y. Nishizawa, A. Shioi, and H. Morii Parathyroid Hormone–Related Peptide as a Local Regulator of Vascular Calcification: Its Inhibitory Action on In Vitro Calcification by Bovine Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., June 1, 1997; 17(6): 1135 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
S. Yamamoto, I. Morimoto, N. Yanagihara, K. Zeki, T. Fujihira, F. Izumi, H. Yamashita, and S. Eto Parathyroid Hormone-Related Peptide-(1-34) [PTHrP- (1-34)] Induces Vasopressin Release from the Rat Supraoptic Nucleus in Vitro through a Novel Receptor Distinct from a Type I or Type II PTH/PTHrP Receptor Endocrinology, May 1, 1997; 138(5): 2066 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jiang, S. Morimoto, K. Fukuo, A. Hirotani, M. Tamatani, T. Nakahashi, A. Nishibe, T. Niinobu, S. Hata, S. Chen, et al. Parathyroid Hormone–Related Protein Inhibits Endothelin-1 Production Hypertension, March 1, 1996; 27(3): 360 - 363. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
